Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Pericytes and vessel maturation during tumor angiogenesis and metastasis.

Raza A, Franklin MJ, Dudek AZ.

Am J Hematol. 2010 Aug;85(8):593-8. doi: 10.1002/ajh.21745. Review.

2.

Targeting the tumor stroma in cancer therapy.

Anton K, Glod J.

Curr Pharm Biotechnol. 2009 Feb;10(2):185-91. Review.

PMID:
19199950
3.

Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.

Rak JW, St Croix BD, Kerbel RS.

Anticancer Drugs. 1995 Feb;6(1):3-18. Review.

PMID:
7538829
4.

Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development.

Olaso E, Vidal-Vanaclocha F.

Methods Mol Med. 2003;85:79-86. Review. No abstract available.

PMID:
12710199
5.

Pericytes and ocular diseases.

Motiejūnaite R, Kazlauskas A.

Exp Eye Res. 2008 Feb;86(2):171-7. Epub 2007 Nov 5. Review.

PMID:
18078933
6.

Angiogenesis in wound healing and tumor metastasis.

Ruiter DJ, Schlingemann RO, Westphal JR, Denijn M, Rietveld FJ, De Waal RM.

Behring Inst Mitt. 1993 Aug;(92):258-72. Review.

PMID:
7504453
7.
8.

Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy.

Ranieri G, Gasparini G.

Curr Drug Targets Immune Endocr Metabol Disord. 2001 Nov;1(3):241-53. Review.

PMID:
12477290
9.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
10.

Endothelial-pericyte interactions in angiogenesis.

Gerhardt H, Betsholtz C.

Cell Tissue Res. 2003 Oct;314(1):15-23. Epub 2003 Jul 22. Review.

PMID:
12883993
11.

Cellular abnormalities of blood vessels as targets in cancer.

Baluk P, Hashizume H, McDonald DM.

Curr Opin Genet Dev. 2005 Feb;15(1):102-11. Review.

PMID:
15661540
12.

Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases.

Chantrain CF, Henriet P, Jodele S, Emonard H, Feron O, Courtoy PJ, DeClerck YA, Marbaix E.

Eur J Cancer. 2006 Feb;42(3):310-8. Epub 2006 Jan 10. Review.

PMID:
16406506
13.

Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies.

Dutour A, Rigaud M.

Anticancer Res. 2005 Nov-Dec;25(6B):3799-807. Review. Erratum in: Anticancer Res. 2006 Jan-Feb;26(1a):445.

14.

The great escape; the hallmarks of resistance to antiangiogenic therapy.

van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW.

Pharmacol Rev. 2015;67(2):441-61. doi: 10.1124/pr.114.010215. Review.

15.

Antiangiogenic cancer therapy.

Cao Y.

Semin Cancer Biol. 2004 Apr;14(2):139-45. Review.

PMID:
15018898
16.

[Angiogenesis and anti-angiogenesis in human neoplasms. Recent developments and the therapeutic prospects].

Vacca A, Ribatti D, Pellegrino A, Dammacco F.

Ann Ital Med Int. 2000 Jan-Mar;15(1):7-19. Review. Italian.

PMID:
10842887
17.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057
18.

Angiogenesis in cancer.

Juczewska M, Chyczewski L.

Rocz Akad Med Bialymst. 1997;42 Suppl 1:86-100. Review.

PMID:
9337527
19.

Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy.

Hall AP.

Toxicol Pathol. 2006;34(6):763-75. Review. No abstract available.

PMID:
17162534
20.

Catecholamines regulate tumor angiogenesis.

Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S.

Cancer Res. 2009 May 1;69(9):3727-30. doi: 10.1158/0008-5472.CAN-08-4289. Epub 2009 Apr 21. Review.

Supplemental Content

Support Center